newsfilter
← Latest News
GlobeNewswire·

argenx Announces Results of Extraordinary General Meeting of Shareholders

  • argenx SE announced results of its Extraordinary General Meeting of shareholders held on November 18, 2025, in Amsterdam.
  • The company's remuneration policy was the sole voting item on the agenda.
  • The remuneration policy was approved by a 95.67% majority vote.
  • 91.1% of the company's share capital was represented at the meeting.
  • Voting results & related documents will be available on the argenx investor website.
  • argenx is a global immunology company developing novel antibody-based medicines for severe autoimmune diseases.
  • The company is commercializing the first approved FcRn blocker & advancing earlier-stage experimental medicines.